

Bell Potter Healthcare Horizons Summit 2026

Schedule & Presenting Company Profiles

Contents

Schedule p2

Company Profiles p3

Contact p8

Bell Potter Healthcare Horizons Summit 2026

Day 1 - Thursday 12 March

8:50AM Welcome

9:00AM **Bell Potter Analyst: Thomas Wakim**
Life sciences market overview: The global perspective

9:30AM **Fireside: John Konstantopoulos (AYA) & Andreas Fouras (4DX)**
Disrupting US healthcare: Opportunities and challenges in the enterprise setting

10:00AM **Fireside: John McCutcheon (EBR) & Barry Regan (SLD)**
The journey to US\$100m revenue in medical devices

10:30AM Morning Tea

11:00AM **Fireside: Margaret Warrington (SNZ) & Stephen Richards (SNZ)**
How ANZ's ageing demographic is reshaping demand

11:30AM **Fireside: Paul Anderson (OCC) & James Agnew (ARX)**
CMS reimbursement: Navigating pricing, margins and adoption

12:00PM **Fireside: Teri Thomas (M7T), Dr Ian Kadish (IDX) & Luke Foster (IDX)**
AI in radiology

12:30PM Lunch

1:00PM - 2:30PM 3x30 minute 1-on-1 presentations between fund managers and companies

2:30PM Afternoon Tea

3:00PM - 5:00PM 4x30 minute 1-on-1 presentations between fund managers and companies

4:55PM Wrap Up

Day 2 - Friday 13 March

8:50AM Welcome

9:00AM **Keynote Speakers: Michael Frazis, Founder and Portfolio Manager at Frazis Capital & Lawrence Gozlan, Investment Manager at Jagen**

9:30AM **Fireside: David Stamler (ATH), Dr Dimitris Voliotis (RAD) & Leslie Chong (IMU)**
Optimising late-stage clinical trials to increase the odds

10:00AM **Fireside: Silviu Itescu (MSB)**
The business of rare disease: Why high margins creates strategic flexibility

10:30AM **Fireside: Michelle Parker (CU6) & Alan Taylor (CU6)**
Commercial readiness: Preparations in entering the massive prostate cancer diagnostic market

11:00AM Morning Tea

11:30AM **Fireside: Jon Pilcher (NEU) & Dr Paul Maruff (CGS)**
Neurological indications: Why the right endpoints can be make or break

12:00PM **Fireside: Christopher Burns (ATX)**
Identifying and developing small molecule drugs

12:30PM Conference Close

Bell Potter Healthcare Horizons Summit 2026



4DMedical (4DX)

Market Cap (A\$)	\$2,317.41m
Company Description	4DMedical is a global MedTech company advancing respiratory care with AI-driven imaging. Its portfolio includes FDA-cleared XV LVAS® and CT LVAS™, anchored by CT:VQ™—a groundbreaking, non-contrast ventilation and perfusion solution redefining cardiothoracic imaging. Delivered via SaaS, 4DMedical empowers earlier diagnosis, precision treatment, and improved patient outcomes.



Amplia Therapeutics (ATX)

Market Cap (A\$)	\$56.44m
Company Description	Amplia Therapeutics is developing the best-in-class small molecule FAK inhibitor for use in solid tumours. The Company has reported promising data from the ACCENT trial in pancreatic cancer. Additional data from this trial and a second trial in the US will be discussed, along with plans for follow-on studies.



Alterity Therapeutics (ATH)

Market Cap (A\$)	\$76.13m
Company Description	Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. Our goal is to modify the course of these diseases and improve quality of life. Their lead asset, ATH434, has the potential to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration.



Aroa Biosurgery (ARX)

Market Cap (A\$)	\$215.92m
Company Description	Aroa Biosurgery is a high-growth medical technology company based in New Zealand. It develops, manufactures and sells innovative soft-tissue repair and wound-healing devices using its proprietary extracellular matrix (ECM) technology. Aroa's products are marketed globally, improving surgical outcomes and supporting regenerative healing across diverse clinical applications.

ARTRYA

Artrya (AYA)

Market Cap (A\$)	\$477.41m
Company Description	Artrya is a medical technology company developing AI-powered solutions to improve the detection and management of coronary artery disease. Its proprietary Salix software analyses coronary CT scans to identify key biomarkers, enabling faster, more accurate diagnosis. Artrya is advancing regulatory and commercial initiatives across global healthcare markets.



Cogstate (CGS)

Market Cap (A\$)	\$366.30m
Company Description	Brain health is profoundly important to quality of life and should be easier to measure. Cogstate provides technology and services for the measurement of cognition to pharmaceutical companies and physicians. Cogstate's market is growing with increased investment in central nervous system diseases following release of breakthrough therapies (e.g. Alzheimer's disease).



Clarity Pharmaceuticals (CU6)

Market Cap (A\$)	\$1,157.01m
Company Description	Clarity is a clinical stage radiopharmaceutical company focused on the treatment of serious diseases. The Company is a leader in innovative radiopharmaceuticals, developing Targeted Copper Theranostics based on its SAR Technology Platform for the treatment of cancers.



EBR Systems (EBR)

Market Cap (A\$)	\$303.92m
Company Description	EBR Systems develops leadless implantable cardiac devices using its proprietary WiSE CRT System technology, enabling wireless left-ventricular endocardial pacing for heart-failure and rhythm management. The company is focused on transforming cardiac resynchronisation therapy by eliminating pacing leads and improving patient outcomes.

Bell Potter Healthcare Horizons Summit 2026



Imugene (IMU)

Market Cap (A\$)	\$77.16m
Company Description	Imugene is a drug developer specialising in developing new agents for various cancer indications. The company has a history of in-licensing early-stage assets, typically pre-clinical or with phase 1 data, and progressing their development. Consequently, the risk of failure is probably high, however the future financial benefit from development of a new chemical entity for disease treatment is immense.



Mach7 Technologies (M7T)

Market Cap (A\$)	\$74.03
Company Description	Mach7 Technologies is a leading provider of medical imaging software, delivering advanced data management and diagnostic viewing solutions to healthcare organisations worldwide. The Mach7 Enterprise Imaging Solution (EIS) is a next-generation solution combining a powerful Vendor Neutral Archive (VNA), the eUnity Enterprise Diagnostic Viewer, and its new Flamingo Architecture.



Integral Diagnostics (IDX)

Market Cap (A\$)	\$901.08
Company Description	Integral Diagnostics is a diagnostic imaging company which operates 145 clinics throughout Australia. IDX offers a range of imaging modalities through its clinics with the largest contribution to revenue sourced from CT and MRI modalities comprising c.60% of revenue. The growth strategy has centred around a combination of greenfield & brownfield investments and M&A opportunities.



Mesoblast (MSB)

Market Cap (A\$)	\$2,607.35m
Company Description	Mesoblast is a global leader in developing allogeneic, off-the-shelf cellular medicines for severe inflammatory diseases. Its FDA-approved therapy RYONCIL (Remestemcel-L) treats paediatric Sr-aGvHD, with further programs targeting adult Sr-aGvHD and inflammatory bowel disease. Rexlemestocel-L is in development for heart failure and chronic low back pain.

Bell Potter Healthcare Horizons Summit 2026



Neuren Pharmaceuticals (NEU)

Market Cap (A\$)	\$1,519.67m
Company Description	Neuren is pioneering therapies for serious neurological disorders with no/limited treatments. DAYBUE™, the world's first and only approved treatment for Rett syndrome, was launched this year in the US by Neuren's licensee Acadia Pharmaceuticals. Neuren's second drug, NNZ-2591, is in Phase 2 trials for Phelan-McDermid, Angelman, Pitt-Hopkins and Prader-Willi syndromes.



Radiopharm Theranostics (RAD)

Market Cap (A\$)	\$74.43m
Company Description	Radiopharm Theranostics is a clinical-stage biotechnology company developing first-in-class radiopharmaceuticals for both diagnostic imaging and therapeutic applications in oncology. The company is advancing a pipeline of antibody, nanobody, peptide and small-molecule platforms targeting cancers with high unmet medical need.



Orthocell (OCC)

Market Cap (A\$)	\$244.18m
Company Description	Orthocell is a regenerative medicine company focused on regenerating mobility for patients. They develop products for the repair of a variety of bone, nerve and tendon injuries. Orthocell's portfolio of products include CelGro™ platform of collagen medical devices which facilitate tissue reconstruction and healing in a variety of dental and orthopaedic reconstructive applications.



Saluda Medical (SLD)

Market Cap (A\$)	\$244.46m
Company Description	Saluda Medical is a commercial-stage medical-device company pioneering a closed-loop neuromodulation platform. Its flagship Evoke System for spinal-cord stimulation senses and adjusts neural activity in real time to treat chronic pain. In the U.S., the company secured FDA approval for its automated programming platform.

Bell Potter Healthcare Horizons Summit 2026



Summerset Group (SNZ)

Market Cap (A\$)	\$2,072.70m
Company Description	Summerset Group is a New Zealand-based company operating as a retirement village and aged care service provider, offering a range of independent living options and care services to over 8,700 residents. They are New Zealand's second-largest operator with 38 villages and properties in Victoria, Australia.

Bell Potter Healthcare Horizons Summit 2026

Contact

To get in touch, please contact your Bell Potter representative to discuss how the team can support your capital markets objectives.

Corporate

James Unger	Head of Corporate Finance	+61 412 670 835	junger@bellpotter.com.au
James Berman	Director - Corporate Finance	+61 404 133 474	jberman@bellpotter.com.au
Michael Gerges	Director - Corporate Finance	+61 422 082 002	mgerges@bellpotter.com.au
Dermott Wilson	Associate Director - Corporate Finance	+61 403 563 028	dwilson@bellpotter.com.au

Corporate Access

Holly Jessop	Head of Corporate Access	+61 448 981 899	hjessop@bellpotter.com.au
Stacey Mastrapas	Executive Assistant / Corporate Access	+61 498 180 772	smastrapas@bellpotter.com.au

Sales

Jason Bailey	Co-Head Institutional Desk	+61 412 880 070	jbailey@bellpotter.com.au
Katharine Lyons	Specialist Healthcare Sales	+61 414 321 127	klyons@bellpotter.com.au


Research

John Hester	Healthcare Analyst	+61 413 874 622	jhester@bellpotter.com.au
Martyn Jacobs	Healthcare Analyst	+61 412 785 180	mjacobs@bellpotter.com.au
Thomas Wakim	Healthcare Analyst	+61 430 183 242	twakim@bellpotter.com.au

Information relayed as part of the Conference is to be considered general investment advice only and does not constitute advice to any person. Although we believe that the advice and information which would be covered and/or provided as part of the Conference is reliable, Bell Potter Securities Limited has not independently verified information which is derived from publicly available sources, directors and management. As such, Bell Potter Securities Limited, its directors, employees and consultants do not represent, warrant or guarantee, expressly or impliedly, that the information that would be presented as part of the Conference is complete or accurate. Should you wish to consider and implement said information/advice, please assess the appropriateness of this information/advice with regard to your objectives, financial situation and needs, because the advice has not taken these factors into account. Bell Potter Securities Limited does not accept any responsibility to inform you of any matter that subsequently comes to its notice, which may affect any of the information presented to you as part of the Conference. Although we are elated to host you for another, please note that you are not under any obligation to attend the Conference.


**Bell Potter
Healthcare
Horizons
Summit
2026**

Notes



**Bell Potter
Healthcare
Horizons
Summit
2026**

Notes



**Bell Potter
Healthcare
Horizons
Summit
2026**

Notes

